FindTrial
Sign In

Postoperative pulmonary complications after sugammadex reversal of neuromuscular blockade in transapical transcatheter aortic valve implantation

Postoperative pulmonary complications after sugammadex reversal of neuromuscular blockade in transapical transcatheter aortic valve implantation

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100044269
Enrollment
Unknown
Registered
2021-03-14
Start date
2021-03-15
Completion date
Unknown
Last updated
2021-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

heart valve disease

Interventions

sugammadex group:Neuromuscular blockade was reversed using sugammadex at the end of the surgery.
neostigmine group:Neuromuscular blockade was reversed using neostigmine at the end of the surgery.

Sponsors

Department of Anesthesiology, West China Hospital of Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: Patients receiving TA-TAVI under general anesthesia with trachea intubation at the West China Hospital between October 2018 and January 2021 were collected retrospectively.

Exclusion criteria

Exclusion criteria: Exclusion criteria included intubation before operating room arrival and extubation in the ICU.

Design outcomes

Primary

MeasureTime frame
postoperative pulmonary complications;—

Secondary

MeasureTime frame
Extubation time;length of hospital stay;ICU time;—

Countries

China

Contacts

Public ContactLiang Peng

Department of Anesthesiology, West China Hospital, Sichuan University

liangpeng_world@foxmail.com+86 18980602201

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 12, 2026